Skip to main content

Table 1 Demographic Data of Participants Completing Cognitive Testing Before and After Intravenous Chemotherapy (n = 142)

From: Immediate-term cognitive impairment following intravenous (IV) chemotherapy: a prospective pre-post design study

Factor Number Percentage
Age, years
 Average 54.7
 Median 55.5
 Range 30–80
Gender
 Male 42 29.6
 Female 100 70.4
Cancer Type
 Breast Cancer 73 51.4
 Colorectal Cancer 69 48.6
Treatment Setting
 Neoadjuvant 19 13.4
 Adjuvant 80 56.3
 Metastatic/Palliative 43 30.3
Prior Chemotherapy Exposure
 Chemotherapy Naïve 17 12.0
 Prior Chemotherapy Exposure 125 88.0
Pre-Chemotherapy Testing Timing
 Same day as chemotherapy 106 74.6
 Day prior to chemotherapy 36 25.4
Antineoplastic Regimen Used
Breast Cancer Regimens
 5-Fluorouracil/Epirubicin/Cyclophosphamide (FEC) 21 14.8
 Docetaxel (D) 21 14.8
 Docetaxel/Cyclophosphamide (DC) 14 9.9
 Paclitaxel (P) 11 7.7
 Docetaxel/Carboplatin (DCARB) 4 2.8
 Doxorubicin/Cyclophosphamide (AC) 2 1.4
Colorectal Cancer Regimens
 5-Fluorouracil/Leucovorin/Oxaliplatin (FOLFOX) 45 31.7
 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI) 11 7.7
 Capecitabine/Oxaliplatin (CAPOX) 9 6.3
 5-Fluorouracil/Leucovorin (FUFA) 2 1.4
 Irinotecan 2 1.4
Additional Antineoplastic Medications Used
 Trastuzumab 16 11.3
 Bevacizumab 12 8.5
 Pertuzumab 2 1.4
 Panitumumab 2 1.4
Supportive Medications Used
 Steroids 142 100.0
 Benzodiazepinesa 0 0.0
 Diphenhydramine 54 38.0
  1. a61 patients (43.0%) had benzodiazepines available for use within their chemotherapy order sets, but medication administration records documented no use of benzodiazepines; 5 patients (3.5%) had separate benzodiazepine prescriptions, use of which would not be documented in the electronic health record